Nifty
Sensex
:
:
18268.40
61350.26
143.00 (0.79%)
383.21 (0.63%)

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 524824 | NSE: BALPHARMA

95.80
26-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  97.35
  •  98.90
  •  95.50
  •  96.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  34049
  •  32.84
  •  137.70
  •  49.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 142.15
  • 15.70
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 248.32
  • 1.04%
  • 1.77

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.87%
  • 0.89%
  • 35.73%
  • FII
  • DII
  • Others
  • 0.15%
  • 0.00%
  • 16.36%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.96
  • 1.82
  • 3.65

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.99
  • 10.73
  • 6.87

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.24
  • 22.05
  • 7.74

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.95
  • 17.55
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.69
  • 1.70
  • 1.50

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.34
  • 12.96
  • 13.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
70.83
52.13
35.87%
0.00
33.77
-100.00%
63.03
43.17
46.00%
64.56
44.99
43.50%
Expenses
63.34
47.05
34.62%
0.00
33.14
-100.00%
57.10
42.47
34.45%
57.46
43.15
33.16%
EBITDA
7.49
5.08
47.44%
0.00
0.63
-100.00%
5.93
0.70
747.14%
7.10
1.83
287.98%
EBIDTM
10.57%
9.75%
0.00%
1.87%
9.41%
1.63%
11.00%
4.07%
Other Income
0.14
0.16
-12.50%
0.00
1.17
-100.00%
0.19
0.41
-53.66%
0.06
0.03
100.00%
Interest
2.97
2.79
6.45%
0.00
3.02
-100.00%
2.89
2.81
2.85%
3.19
3.33
-4.20%
Depreciation
2.19
1.88
16.49%
0.00
3.59
-100.00%
2.03
1.42
42.96%
2.17
1.35
60.74%
PBT
2.46
0.57
331.58%
0.00
-4.80
-
1.20
-3.11
-
1.81
-2.83
-
Tax
0.81
0.29
179.31%
0.00
-0.07
-
0.80
0.60
33.33%
1.31
-0.84
-
PAT
1.65
0.28
489.29%
0.00
-4.74
-
0.40
-3.71
-
0.50
-1.99
-
PATM
2.33%
0.54%
0.00%
-14.02%
0.64%
-8.58%
0.77%
-4.42%
EPS
1.09
0.30
263.33%
0.00
-3.34
-
0.22
-2.52
-
0.30
-1.29
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 11
Mar 10
Net Sales
-
250.53
171.09
225.01
209.29
228.91
198.32
187.16
178.87
114.29
106.23
Net Sales Growth
-
46.43%
-23.96%
7.51%
-8.57%
15.42%
5.96%
4.63%
56.51%
7.59%
 
Cost Of Goods Sold
-
140.87
75.74
104.04
88.57
103.94
94.06
87.49
83.74
54.71
55.24
Gross Profit
-
109.66
95.35
120.96
120.71
124.97
104.25
99.67
95.14
59.58
50.99
GP Margin
-
43.77%
55.73%
53.76%
57.68%
54.59%
52.57%
53.25%
53.19%
52.13%
48.00%
Total Expenditure
-
225.88
166.07
207.33
191.95
214.10
183.46
170.05
161.00
104.36
100.95
Power & Fuel Cost
-
4.98
4.76
6.38
6.07
6.17
4.66
4.54
4.39
2.90
2.13
% Of Sales
-
1.99%
2.78%
2.84%
2.90%
2.70%
2.35%
2.43%
2.45%
2.54%
2.01%
Employee Cost
-
41.88
50.44
50.28
52.16
45.37
37.30
32.24
28.12
20.58
19.73
% Of Sales
-
16.72%
29.48%
22.35%
24.92%
19.82%
18.81%
17.23%
15.72%
18.01%
18.57%
Manufacturing Exp.
-
18.61
15.80
20.28
18.03
21.44
19.80
20.78
18.23
11.24
8.90
% Of Sales
-
7.43%
9.23%
9.01%
8.61%
9.37%
9.98%
11.10%
10.19%
9.83%
8.38%
General & Admin Exp.
-
5.45
7.48
9.27
11.21
16.82
13.98
12.43
11.54
5.41
4.71
% Of Sales
-
2.18%
4.37%
4.12%
5.36%
7.35%
7.05%
6.64%
6.45%
4.73%
4.43%
Selling & Distn. Exp.
-
10.27
10.61
15.74
15.63
19.50
13.18
11.91
13.49
8.73
9.62
% Of Sales
-
4.10%
6.20%
7.00%
7.47%
8.52%
6.65%
6.36%
7.54%
7.64%
9.06%
Miscellaneous Exp.
-
3.84
1.23
1.33
0.27
0.86
0.47
0.65
1.48
0.78
9.62
% Of Sales
-
1.53%
0.72%
0.59%
0.13%
0.38%
0.24%
0.35%
0.83%
0.68%
0.58%
EBITDA
-
24.65
5.02
17.68
17.34
14.81
14.86
17.11
17.87
9.93
5.28
EBITDA Margin
-
9.84%
2.93%
7.86%
8.29%
6.47%
7.49%
9.14%
9.99%
8.69%
4.97%
Other Income
-
1.14
1.85
1.01
1.73
3.04
1.28
1.17
0.65
0.79
2.94
Interest
-
12.16
12.73
12.74
9.41
8.49
6.48
6.52
7.16
6.79
6.26
Depreciation
-
9.52
7.68
6.16
6.77
6.49
7.01
7.02
4.74
2.90
2.86
PBT
-
4.10
-13.53
-0.20
2.88
2.87
2.65
4.74
6.63
1.04
-0.91
Tax
-
-0.61
-0.64
-2.36
2.51
3.27
2.39
1.19
1.55
0.63
0.52
Tax Rate
-
-14.88%
4.73%
1180.00%
87.15%
113.94%
90.19%
25.11%
23.38%
60.58%
-57.14%
PAT
-
4.74
-12.22
3.79
2.79
1.75
1.41
3.62
5.07
0.41
-1.43
PAT before Minority Interest
-
4.71
-12.89
2.15
0.38
-0.40
0.26
3.55
5.07
0.41
-1.43
Minority Interest
-
0.03
0.67
1.64
2.41
2.15
1.15
0.07
0.00
0.00
0.00
PAT Margin
-
1.89%
-7.14%
1.68%
1.33%
0.76%
0.71%
1.93%
2.83%
0.36%
-1.35%
PAT Growth
-
-
-
35.84%
59.43%
24.11%
-61.05%
-28.60%
1,136.59%
-
 
EPS
-
3.20
-8.26
2.56
1.89
1.18
0.95
2.45
3.43
0.28
-0.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 11
Mar 10
Shareholder's Funds
53.58
52.43
66.64
64.99
62.45
54.90
55.20
50.05
36.18
35.76
Share Capital
14.82
14.17
14.17
14.17
14.17
12.87
12.87
11.11
10.48
10.48
Total Reserves
37.82
38.25
52.47
50.82
48.27
40.01
40.31
37.20
25.50
25.09
Non-Current Liabilities
34.19
33.56
37.85
45.57
30.02
45.12
16.34
17.92
64.54
60.66
Secured Loans
23.93
22.93
28.76
33.25
12.76
15.24
6.11
6.58
53.76
54.41
Unsecured Loans
0.00
0.22
0.00
1.43
5.04
19.71
0.53
1.39
3.97
0.01
Long Term Provisions
4.07
3.62
2.71
2.05
3.42
2.28
1.65
1.06
0.00
0.00
Current Liabilities
152.53
159.49
163.24
154.40
143.24
111.19
92.36
86.77
34.59
27.78
Trade Payables
47.17
38.67
47.34
49.96
54.43
46.85
38.53
33.53
27.02
22.07
Other Current Liabilities
23.57
30.69
27.86
33.77
16.45
12.01
11.86
8.66
6.03
4.73
Short Term Borrowings
80.82
89.63
87.08
68.31
71.07
50.09
40.14
42.75
0.00
0.00
Short Term Provisions
0.98
0.50
0.96
2.37
1.29
2.24
1.83
1.83
1.53
0.99
Total Liabilities
240.07
238.38
261.31
260.17
233.33
211.03
163.87
154.74
135.31
124.20
Net Block
68.59
70.71
70.39
71.48
59.98
56.23
52.20
55.18
54.26
54.98
Gross Block
105.10
97.70
89.76
84.71
66.44
106.10
95.14
90.11
76.86
74.11
Accumulated Depreciation
36.52
27.00
19.37
13.23
6.46
49.87
42.95
34.93
22.60
19.13
Non Current Assets
75.93
81.02
78.26
75.41
68.78
68.03
58.74
59.63
54.40
55.00
Capital Work in Progress
0.00
3.32
3.63
0.21
1.70
3.93
0.77
0.25
0.13
0.00
Non Current Investment
0.00
0.00
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Long Term Loans & Adv.
4.86
5.43
1.69
3.15
6.61
7.54
5.42
3.95
0.00
0.00
Other Non Current Assets
2.49
1.56
2.54
0.55
0.46
0.32
0.34
0.24
0.00
0.00
Current Assets
164.15
157.37
183.05
184.77
164.55
143.00
105.12
95.12
80.90
69.20
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
60.39
67.71
69.75
66.49
54.73
41.75
35.82
31.71
32.21
28.62
Sundry Debtors
67.20
49.60
64.70
64.05
61.80
56.94
44.98
45.49
37.02
31.92
Cash & Bank
3.85
3.13
4.32
4.15
4.71
4.63
5.49
3.02
2.23
1.61
Other Current Assets
32.71
4.07
0.70
0.24
43.31
39.66
18.83
14.89
9.44
7.05
Short Term Loans & Adv.
28.02
32.85
43.58
49.83
42.45
38.45
17.48
13.96
5.56
4.59
Net Current Assets
11.61
-2.12
19.81
30.36
21.31
31.81
12.77
8.35
46.31
41.42
Total Assets
240.08
238.39
261.31
260.18
233.33
211.03
163.86
154.75
135.30
124.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 11
Mar 10
Cash From Operating Activity
21.78
23.24
7.76
0.58
6.31
-19.35
14.53
13.31
4.61
-5.22
PBT
4.10
-13.53
-0.20
2.88
2.87
2.65
4.74
6.63
1.04
-0.91
Adjustment
21.14
19.01
17.41
15.14
14.79
11.46
11.69
10.43
9.49
7.12
Changes in Working Capital
-3.35
17.94
-7.07
-16.18
-9.95
-32.66
-0.59
-2.59
-6.10
-10.70
Cash after chg. in Working capital
21.89
23.42
10.13
1.84
7.72
-18.55
15.84
14.47
4.43
-4.48
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.11
-0.17
-2.38
-1.27
-1.40
-0.80
-1.31
-1.16
0.18
-0.74
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4.98
-4.71
-8.04
-3.56
-7.96
-13.88
-5.30
-7.30
-1.59
4.61
Net Fixed Assets
-3.66
-6.22
-4.61
-3.80
41.86
-12.93
-5.24
-15.62
-2.86
-6.26
Net Investments
-0.98
0.02
0.00
-7.42
1.16
-0.09
-1.07
0.04
0.00
0.03
Others
-0.34
1.49
-3.43
7.66
-50.98
-0.86
1.01
8.28
1.27
10.84
Cash from Financing Activity
-16.63
-19.97
0.01
3.53
-5.94
32.37
-6.80
-7.52
-2.40
0.74
Net Cash Inflow / Outflow
0.17
-1.44
-0.27
0.55
-7.58
-0.86
2.43
-1.51
0.62
0.13
Opening Cash & Equivalents
0.86
2.44
2.71
2.16
-17.72
5.49
3.02
4.53
1.61
1.49
Closing Cash & Equivalent
1.02
0.86
2.44
2.71
-25.30
4.63
5.45
3.02
2.23
1.61

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 11
Mar 10
Book Value (Rs.)
35.52
36.99
47.02
45.86
44.06
41.09
41.32
43.48
34.33
33.94
ROA
1.97%
-5.16%
0.83%
0.15%
-0.18%
0.14%
2.23%
3.50%
0.31%
-1.16%
ROE
8.97%
-21.65%
3.27%
0.59%
-0.69%
0.49%
7.00%
12.03%
1.14%
-4.22%
ROCE
9.72%
-0.44%
6.88%
7.45%
7.59%
7.35%
10.88%
14.05%
8.51%
6.31%
Fixed Asset Turnover
2.47
1.83
2.58
2.80
2.72
2.01
2.06
2.18
1.60
1.58
Receivable days
85.08
121.92
104.42
108.60
92.23
91.87
86.58
82.73
104.23
99.58
Inventory Days
93.31
146.63
110.50
104.61
74.94
69.91
64.63
64.10
91.99
85.43
Payable days
72.54
90.28
86.70
99.47
88.16
89.31
79.05
72.93
89.00
77.88
Cash Conversion Cycle
105.86
178.27
128.22
113.74
79.02
72.47
72.17
73.90
107.22
107.13
Total Debt/Equity
2.09
2.26
1.85
1.69
1.49
1.68
0.93
1.08
1.60
1.53
Interest Cover
1.34
-0.06
0.98
1.31
1.34
1.41
1.73
1.93
1.15
0.86

News Update:


  • Bal Pharma poised to strengthen its position in diabetes segment
    28th Sep 2021, 14:01 PM

    Gliclazide, API is a sulfonyl urea component used for treating type 2 Diabetes, has been an important contributor in the company’s earnings

    Read More
  • Bal Pharma reports around 4-fold jump in Q1 consolidated net profit
    11th Aug 2021, 13:09 PM

    Total consolidated income of the company increased by 35.72% at Rs 70.96 crore for Q1FY22

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.